News 
Market Data 
Discover
Replies to post #83465 on Anavex Life Sciences Corp (AVXL)
makemydaze Wednesday, 04/13/16 08:29:42 AM
Re: georgejjl post# 59096
Post #59099 of 83471
Jackie French will be there but she is affiliated with so many companies that it may not mean anything for Anavex specifically.
"Jacqueline French
(Education Program, Science Program) (C169, PL6, P2, S22, I5)
The Epilepsy Study Consortium pays Dr French’s university employer for her consultant time related to Acorda, Alexza, Anavex, BioPharm Solutions, Concert Pharmaceuticals, Eisai, Georgia Regents University, GW Pharma, Marinus, Monteris, Nestle-Health Science, Neurelis, Novartis, Pfizer, Pfizer-Neusentis, Pronutria, Roivant, Sage, SciFluor, SK Life Sciences, Sunovion, Takeda, UCB Inc., Upsher Smith, Xenon Pharmaceuticals, Zogenix.. Personal compensation for Associate Editor Epilepsia. She has received grants and research from Acorda, Alexza, LCGH, Eisai Medical Research, Lundbeck, Pfizer, SK life sciences, UCB, Upsher-Smith, Vertex, grants from NINDS, Epilepsy Therapy Project, Epilepsy Research Foundation, Epilepsy Study Consortium."
http://tools.aan.com/annualmeeting/search/index.cfm?fuseaction=disclosures.home&meetingyear=2016&lastname=french&search=Search
There is no "Missling" listed but feel free to search for any of your favorite Anavex stars.
XenaLives Member Level Friday, 06/17/16 02:23:14 AM
Re: None
Post #65372 of 83471
Example of Takeda licensing deal - this is GI but they also focus on CNS. $15 million up front. Alzheimer's is a much bigger market.
http://finance.yahoo.com/news/takeda-licenses-global-rights-theravance-122900801.html
XenaLives Member Level Friday, 09/16/16 07:42:21 AM
Re: georgejjl post# 75321
Post #75322 of 83471
About Agreement Reached to Co-market R113675 (Galantamine Hydrobromide),
a Treatment for Alzheimer's Disease
OSAKA, Japan, April 1, 2010 --- Takeda Pharmaceutical Company Limited (“Takeda”) today announced that it has signed an agreement dated March 31, 2010 with JANSSEN PHARMACEUTICAL K.K. (Head Office: Tokyo, President: Toon Overstijns, hereinafter called “Janssen Pharma”) and Janssen Pharmaceutica N.V. (Head Office: Belgium, Managing Director: Tom Heyman) regarding co-marketing in Japan of galantamine (R113675), which is a drug for Alzheimer's Disease and chemically known as galantamine hydrobromide (hereinafter called “galantamine”).
Following the development of galantamine by Janssen Pharmaceutica, for the treatment of Alzheimer’s Disease in Japan, Janssen Pharma submitted an application for approval to the Ministry of Health, Labor and Welfare in February 2010. Once approved, Takeda and Janssen Pharma will co-market galantamine under the same brand name.
Under the agreement, Takeda receives rights to co-market galantamine in Japan, and will make an upfront contractual payment, as well as launch & annual sales milestone payments to Janssen Pharma and Janssen Pharmaceutica. In addition, Takeda will pay a fixed rate based on sales. Other contractual details are not disclosed.
For Takeda, this agreement will expand and improve its domestic pipeline in CNS (central nervous system) which is one of Takeda’s core therapeutic disease areas. After receiving approval, we look forward to offering a new treatment option for patients suffering from Alzheimer’s Disease, their families and healthcare professionals. At Takeda, we are committed to making continued effort to research, develop and market new medicines that address unmet medical needs.
About Galantamine
Galantamine has a dual mechanism which affect acetylcholinesterase inhibition and nicotinic acetylcholine receptor enhancement that increases concentration of acetylcholine, a key neurotransmitter in the brain. First approved in 2000 in Europe, it has been launched in more than 70 countries around the world. In major treatment guidelines, galantamine is positioned as one of the standard therapies for “mild to moderate Alzheimer’s Disease”.
ipulator_man Monday, 07/04/16 02:38:59 PM
Re: basparks79 post# 66858
Post # of 83471
Check out this guy's work:
"Dr. Castellani, Ms. Gupta, Ms. Siedlak, Ms. Harris, Dr. Coller, and Dr. Tabaton report no conflict of interests. Dr. Perry is a consultant for Takeda Pharmaceuticals and Neurotez and owns stock options in Neurotez and Voyager. Dr. Zhu was a consultant for and received grant support from Medivation. Dr. Smith was a consultant for Anavex Life Sciences Corporation, Eisai, Medivation, Neurotez, and Takeda Pharmaceuticals; owned stock options in Aria Neurosciences, Neurotez, Panancea, and Voyager, and had received lecture fees from GSK, Medivation, and Pfizer."
He had just joined the team when he died in 2010.
http://www.case.edu/med/pathology/faculty/smith.html
The MOA of Anavex' compounds tie in with his theories precisely. He would have been a powerful ally.
§
makemydaze Wednesday, 04/13/16 08:29:42 AM
Re: georgejjl post# 59096
Post #59099 of 83471
Jackie French will be there but she is affiliated with so many companies that it may not mean anything for Anavex specifically.
"Jacqueline French
(Education Program, Science Program) (C169, PL6, P2, S22, I5)
The Epilepsy Study Consortium pays Dr French’s university employer for her consultant time related to Acorda, Alexza, Anavex, BioPharm Solutions, Concert Pharmaceuticals, Eisai, Georgia Regents University, GW Pharma, Marinus, Monteris, Nestle-Health Science, Neurelis, Novartis, Pfizer, Pfizer-Neusentis, Pronutria, Roivant, Sage, SciFluor, SK Life Sciences, Sunovion, Takeda, UCB Inc., Upsher Smith, Xenon Pharmaceuticals, Zogenix.. Personal compensation for Associate Editor Epilepsia. She has received grants and research from Acorda, Alexza, LCGH, Eisai Medical Research, Lundbeck, Pfizer, SK life sciences, UCB, Upsher-Smith, Vertex, grants from NINDS, Epilepsy Therapy Project, Epilepsy Research Foundation, Epilepsy Study Consortium."
http://tools.aan.com/annualmeeting/search/index.cfm?fuseaction=disclosures.home&meetingyear=2016&lastname=french&search=Search
There is no "Missling" listed but feel free to search for any of your favorite Anavex stars.
XenaLives Member Level Friday, 06/17/16 02:23:14 AM
Re: None
Post #65372 of 83471
Example of Takeda licensing deal - this is GI but they also focus on CNS. $15 million up front. Alzheimer's is a much bigger market.
http://finance.yahoo.com/news/takeda-licenses-global-rights-theravance-122900801.html
XenaLives Member Level Friday, 09/16/16 07:42:21 AM
Re: georgejjl post# 75321
Post #75322 of 83471
About Agreement Reached to Co-market R113675 (Galantamine Hydrobromide),
a Treatment for Alzheimer's Disease
OSAKA, Japan, April 1, 2010 --- Takeda Pharmaceutical Company Limited (“Takeda”) today announced that it has signed an agreement dated March 31, 2010 with JANSSEN PHARMACEUTICAL K.K. (Head Office: Tokyo, President: Toon Overstijns, hereinafter called “Janssen Pharma”) and Janssen Pharmaceutica N.V. (Head Office: Belgium, Managing Director: Tom Heyman) regarding co-marketing in Japan of galantamine (R113675), which is a drug for Alzheimer's Disease and chemically known as galantamine hydrobromide (hereinafter called “galantamine”).
Following the development of galantamine by Janssen Pharmaceutica, for the treatment of Alzheimer’s Disease in Japan, Janssen Pharma submitted an application for approval to the Ministry of Health, Labor and Welfare in February 2010. Once approved, Takeda and Janssen Pharma will co-market galantamine under the same brand name.
Under the agreement, Takeda receives rights to co-market galantamine in Japan, and will make an upfront contractual payment, as well as launch & annual sales milestone payments to Janssen Pharma and Janssen Pharmaceutica. In addition, Takeda will pay a fixed rate based on sales. Other contractual details are not disclosed.
For Takeda, this agreement will expand and improve its domestic pipeline in CNS (central nervous system) which is one of Takeda’s core therapeutic disease areas. After receiving approval, we look forward to offering a new treatment option for patients suffering from Alzheimer’s Disease, their families and healthcare professionals. At Takeda, we are committed to making continued effort to research, develop and market new medicines that address unmet medical needs.
About Galantamine
Galantamine has a dual mechanism which affect acetylcholinesterase inhibition and nicotinic acetylcholine receptor enhancement that increases concentration of acetylcholine, a key neurotransmitter in the brain. First approved in 2000 in Europe, it has been launched in more than 70 countries around the world. In major treatment guidelines, galantamine is positioned as one of the standard therapies for “mild to moderate Alzheimer’s Disease”.
ipulator_man Monday, 07/04/16 02:38:59 PM
Re: basparks79 post# 66858
Post #66866 of 83471
Check out this guy's work:
"Dr. Castellani, Ms. Gupta, Ms. Siedlak, Ms. Harris, Dr. Coller, and Dr. Tabaton report no conflict of interests. Dr. Perry is a consultant for Takeda Pharmaceuticals and Neurotez and owns stock options in Neurotez and Voyager. Dr. Zhu was a consultant for and received grant support from Medivation. Dr. Smith was a consultant for Anavex Life Sciences Corporation, Eisai, Medivation, Neurotez, and Takeda Pharmaceuticals; owned stock options in Aria Neurosciences, Neurotez, Panancea, and Voyager, and had received lecture fees from GSK, Medivation, and Pfizer."
He had just joined the team when he died in 2010.
http://www.case.edu/med/pathology/faculty/smith.html
The MOA of Anavex' compounds tie in with his theories precisely. He would have been a powerful ally.
§
XenaLives Member Level Thursday, 09/15/16 06:21:57 AM
Re: None
Post #75180 of 83472
Takeda would be a great partner for Anavex -
Quote:Japan's Takeda Pharmaceutical on hunt for overseas deals
By Ben Hirschler | LONDON
Takeda Pharmaceutical (4502.T), Japan's largest drugmaker, is scouting for potential multibillion-dollar acquisitions in the United States and other overseas markets as it seeks to reduce its dependence on domestic sales, which are proving sluggish.
Chief Executive Christophe Weber told Reuters on Wednesday that he is now more open to deals after refocusing the company on three key therapeutic areas and launching an overhaul of its research activities.
"We are much more organised and ready to do something now than one year ago," he said in a telephone interview. "We are very active and we are looking at opportunities."
Weber, a French national who took over as the company's first foreign boss last year, is on a mission to make Takeda a truly global pharmaceuticals business, arguing that this requires greater investment and expansion outside Japan.
ADVERTISING
inRead invented by Teads
At the end of July he set out plans for a 75 billion-yen ($725 million) reorganization of research and development by concentrating R&D efforts in the United States and Japan.
That revamp is part of a broader streamlining process designed to make the company a force to be reckoned with in its core therapy areas of cancer, gastrointestinal (GI) and central nervous system (CNS) medicine, plus vaccines.
Cancer treatment is a target for many large drugmakers, with high prices being paid for promising assets, such as Medivation (MDVN.O), which was sold last month for $14 billion after Pfizer (PFE.N) trumped an initial bid from Sanofi (SASY.PA) with a 55 percent higher offer.
"There is less competition in GI and CNS, but there is also less innovation. The oncology field is moving at a very fast pace," Weber said.
He said he would be happy to see Takeda's ratio of net debt to earnings before interest, tax, depreciation and amortization rise to 2, or slightly more, but he declined to confirm a report in the Financial Times that the company had set aside $10 billion to $15 billion for acquisitions.
Takeda's current net debt to EBITDA ratio is less than 1.
"We want to remain investment grade," Weber said. "Investment grade could mean two times EBITDA, perhaps a little bit higher in the short term."
PIPELINE BUILDING
Takeda's last major deal was in 2011 when it paid nearly $14 billion for Swiss drug company Nycomed, which greatly expanded its presence in emerging
Now, however, the focus of Weber and his new research head Andy Plump is on building up the pipeline of novel medicines so Takeda has market-leading new treatments to replace older ones facing patent expiry.
The company's top-selling blood cancer drug Velcade faces generic competition in 2017 and other key products will go off patent from 2020.
New drugs Entyvio, for ulcerative colitis, and Ninlaro, a follow-on to Velcade, have made a promising start but Weber is conscious he needs to do more to ensure growth and boost margins.
"We are now much more focusing on the reinforcement of our pipeline because this is where we need to do something, so that in five years, when we start to see more significant patent expiries, we will have a pipeline to replace that," he said.
In recent weeks the company has already picked up the pace of smaller-scale deal-making, including a stem-cell agreement with Belgium's TiGenix (G9U.BR). It has also signaled its global ambitions in vaccines by advancing plans for trials for shots against dengue and Zika.
(Editing by Greg Mahlich)
http://www.reuters.com/article/us-takeda-ceo-idUSKCN11K1DM
